Leonard C Glass

Leonard C Glass

Eli Lilly and Company - Indianapolis / United States
Others
AD Scientific Index ID: 4385817
-
person_outline Leonard C Glass's MOST POPULAR ARTICLES
1-) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetesG Gaich, JY Chien, H Fu, LC Glass, MA Deeg, WL Holland, ...Cell metabolism 18 (3), 333-340, 20138372013
2-) Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemiaE Wright Jr, JL Scism‐Bacon, LC GlassInternational journal of clinical practice 60 (3), 308-314, 20066372006
3-) Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized, controlled trialJB Buse, RM Bergenstal, LC Glass, CR Heilmann, MS Lewis, AYM Kwan, ...Annals of internal medicine 154 (2), 103-112, 20116202011
4-) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazoneY Miyazaki, A Mahankali, M Matsuda, L Glass, S Mahankali, E Ferrannini, ...Diabetes care 24 (4), 710-719, 20015802001
5-) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patientsM Bajaj, S Suraamornkul, P Piper, LJ Hardies, L Glass, E Cersosimo, ...The journal of clinical endocrinology & metabolism 89 (1), 200-206, 20044682004